Analyses of muscular mass and function: the impact on bone mineral density and peak muscle mass.
Bone density and bone mass are commonly regarded as the essential parameters to describe fracture risk in osteology. Because fractures primarily depend on bone strength and secondarily on bone mass and density, bone strength should be the main parameter to describe fracture risk. The quantitative description of bone strength has the prerequisite that bone geometry is assessed despite bone density. Thus, volumetric osteodensitometric methods should be preferred, which enable the physician to evaluate parameters primarily associated with bone modeling or remodeling. Modeling describes the adaptation of bone geometry to applied muscular forces in contrast to remodeling representing bone turnover. The adaptation of bone geometry to muscle forces led to the term functional muscle-bone unit, which enables the physician to differentiate between primary and secondary bone diseases. Primary bone diseases are characterized by a defective adaptation of bone to muscle forces in contrast to secondary bone diseases, which are primary diseases of the neuromuscular system. Because muscle forces are essential in the feedback loop of bone adaptation to forces (mechanostat), the assessment of muscle function has become an essential part of osteologic diagnostics in pediatrics. Dynamometric and mechanographic methods have been introduced to properly characterize kinetic aspects of muscle function in children and adolescents. Therefore, emphasis should be put on the assessment of muscle function despite the evaluation of osteodensitometric parameters in pediatric osteology.
Fricke
Oliver
O
University of Cologne, Kerpener Strasse 62, Cologne, Germany. frickeo@uni-koeln.de
Beccard
Ralf
R
Semler
Oliver
O
Schoenau
Eckhard
E
D000293:Adolescent; D000367:Age Factors; D001696:Biomechanical Phenomena; D015519:Bone Density; D001846:Bone Development; D002648:Child; D050723:Fractures, Bone / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007700:Kinetics; D008954:Models, Biological; D018482:Muscle, Skeletal / Q000254:growth & development / Q000473:pathology* / Q000503:physiopathology; D009929:Organ Size; D010024:Osteoporosis / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D018570:Risk Assessment; D012307:Risk Factors
Am J Physiol Cell Physiol. 2007 Jan;292(1):C545-52
16885390
Pediatr Res. 2001 Sep;50(3):309-14
11518815
J Bone Miner Res. 2009 Oct;24(10):1693-8
19419294
Horm Res Paediatr. 2010;73(5):390-7
20389111
Pediatr Nephrol. 2000 Jul;14(7):669-72
10912540
Eur J Pediatr. 1996 May;155(5):349-50
8741028
Bone. 2007 Oct;41(4):486-95
17706477
Osteoporos Int. 2010 Jan;21(1):11-23
19504035
J Bone Miner Res. 2002 Jun;17(6):1095-101
12054165
Eur J Endocrinol. 2004 Aug;151 Suppl 1:S87-91
15339251
Calcif Tissue Int. 2002 May;70(5):405-7
11960207
Kidney Int. 2004 Oct;66(4):1694-706
15458468
Eur J Pediatr. 2008 Mar;167(3):331-6
17516086
J Clin Endocrinol Metab. 2001 Feb;86(2):613-8
11158018
Pediatrics. 2006 Feb;117(2):e291-7
16452336
Am J Hum Biol. 1998;10(5):599-605
28561546
Calcif Tissue Int. 1998 Jan;62(1):1-7
9405724
J Nutr. 2008 Oct;138(10):1835-9
18806089
Bone. 1995 Aug;17(2):157-9
8554924
Pediatr Nephrol. 2004 Aug;19(8):825-31
15197638
J Musculoskelet Neuronal Interact. 2001 Dec;2(2):121-30
15758459
Nature. 2005 Jul 21;436(7049):347-55
16034409
Calcif Tissue Int. 1999 Mar;64(3):267-70
10024389
J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):232-8
16172514
J Clin Densitom. 2008 Apr-Jun;11(2):283-94
18164637
Bone. 2001 Feb;28(2):227-32
11182383
Pediatr Res. 2006 Jan;59(1):46-9
16327004
J Clin Endocrinol Metab. 2000 Mar;85(3):1095-8
10720045
Osteoporos Int. 2008 Oct;19(10):1369-78
18633664
J Bone Miner Res. 2006 Sep;21(9):1489-95
16939408
J Bone Miner Res. 1994 Aug;9(8):1137-41
7976495
J Musculoskelet Neuronal Interact. 2005 Jun;5(2):155-61
15951632
Osteoporos Int. 1999;10(4):259-64
10692972
Bone. 1998 Jun;22(6):683-90
9626409
Pediatr Res. 2002 Apr;51(4):505-10
11919337
Bone. 1998 Jan;22(1):1-6
9437507
Eur J Endocrinol. 2008 Dec;159 Suppl 1:S27-31
18787052
Rev Endocr Metab Disord. 2008 Jun;9(2):131-7
18175221
J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):225-31
16172513
Bone. 2009 Sep;45(3):512-6
19497394
J Bone Miner Metab. 2000;18(6):305-16
11052462